Every Form 4 that BioNTech (BNTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BNTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BNTX filings page.
BioNTech SE (BNTX) reports that Chief Executive Officer and ten percent owner Ugur Sahin sold a total of 64,000 Ordinary Shares in open-market or private transactions on September 17–18, 2026, at weighted-average prices of $98.5983 and $96.2243 per share, respectively, under a Rule 10b5-1 trading plan established on June 3, 2026.
Following these transactions, an entity associated with Sahin, Medine GmbH, holds 39,218,111 Ordinary Shares indirectly attributed to him, including 106,721 Ordinary Shares held in trust where Medine GmbH exercises voting power but not dispositive power, and Sahin may be deemed to beneficially own these shares.
BioNTech SE (BNTX) Chief Executive Officer and ten percent owner Ugur Sahin reported open-market sales of BioNTech ordinary shares under a pre-arranged Rule 10b5-1 trading plan established on June 3, 2026. He sold 15,000 ordinary shares on September 16, 2026 at an average price of $96.0893 per share and 34,000 ordinary shares on September 15, 2026 at an average price of $96.4893 per share, for total reported sales of 49,000 shares.
Following these transactions, a reported 39,218,111 ordinary shares are held indirectly through Medine GmbH, of which Sahin is the sole shareholder. The filing notes that 106,721 of these shares are held in trust, where Medine GmbH has voting but not dispositive power, and that Sahin may be deemed to beneficially own the shares held by Medine GmbH.
BioNTech SE (BNTX) reported that Chief Executive Officer and major shareholder Ugur Sahin sold a total of 86,000 ordinary shares in mid-September 2026 under a pre-arranged trading plan. He sold 41,000 shares on September 14, 2026 at an average price of 99.4467 per share and 45,000 shares on September 11, 2026 at an average price of 96.9338 per share.
After these sales, an entity associated with him, Medine GmbH, held 39,218,111 ordinary shares indirectly, including 106,721 shares held in trust where Medine GmbH has voting power but not dispositive power. The sales were effected pursuant to a Rule 10b5-1 trading plan established on June 3, 2026.
BioNTech SE (BNTX) reports that Chief Executive Officer and ten percent owner Ugur Sahin sold 20,500 Ordinary Shares on September 10, 2026 in an open-market or private transaction at $96.31 per share, under a Rule 10b5-1 trading plan established on June 3, 2026. Following this sale, he holds 688,209 Ordinary Shares directly and 39,218,111 Ordinary Shares indirectly through Medine GmbH, including 106,721 shares held in trust where Medine GmbH has voting but not dispositive power and Sahin may be deemed to beneficially own those shares.
BioNTech SE (BNTX) reported that Chief Executive Officer and ten percent owner Ugur Sahin sold ordinary shares in two open-market or private transactions under a pre-arranged Rule 10b5-1 trading plan established on June 3, 2026. On September 8 and 9, 2026 he sold an aggregate of 73,000 ordinary shares. An indirectly held position of 39,218,111 ordinary shares, mainly through Medine GmbH, is reported after these transactions.
BioNTech SE (BNTX) reported that Chief Executive Officer Ugur Sahin sold a total of 76,500 Ordinary Shares in open-market transactions pursuant to a Rule 10b5-1 trading plan established on June 3, 2026. The sales occurred on September 3 and September 4, 2026 at prices just above $102 and $103 per share.
BioNTech SE Chief Financial Officer Ramon Zapata Gomez received new equity-based compensation. He was granted 15,103 Performance Share Units and 18,879 options, each tied to one ordinary share. The options carry an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, or cash.
Both the PSUs and options vest annually in equal installments over four years starting on the first anniversary of the grant. They become exercisable four years after the grant date and are subject to performance and other conditions, including share-price targets relative to the Nasdaq Biotechnology Index.
BioNTech SE reported new equity awards to officer Ryan James Timothy Patrick. On May 12, 2026, he received 10,069 Performance Share Units and an option over 12,586 ordinary shares as compensation, both at a grant price of zero.
The option carries an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, or cash at the supervisory board’s election. Both the PSUs and options vest in equal annual installments over four years starting on the first anniversary of the grant date and become exercisable four years after grant, subject to performance and service conditions. PSU performance targets are based on BioNTech’s share price relative to the Nasdaq Biotechnology Index.
BioNTech SE Chief Operating Officer Sierk Poetting reported compensation-related equity grants. He received 10,069 Performance Share Units and 12,586 options, each linked to ordinary shares. These awards were granted at no cash cost to him and are classified as derivative securities.
The options carry an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, or cash at the supervisory board’s election. Both the options and PSUs vest annually in equal installments over four years starting on the first anniversary of the grant date and become exercisable four years after the grant date, subject to specified performance and service conditions.
BioNTech SE reported that Chief People Officer Kylie Jimenez received new equity-based compensation. She was granted 8,391 performance share units, each economically equivalent to one ordinary share, and options over 10,488 ordinary shares.
The performance share units and options both vest annually in equal installments over four years starting on the first anniversary of the grant date and become exercisable four years after the grant date, subject to performance-based and other conditions. The option has an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, and/or cash at the supervisory board’s election.
BioNTech SE Chief Commercial Officer Annemarie Hanekamp received new equity-based compensation awards. She was granted 10,069 performance share units and options on 12,586 ordinary shares, both with no upfront purchase price. The options have an exercise price of EUR 89.38 and may be settled in shares, ADSs, or cash at the supervisory board’s election. Both the options and PSUs vest in equal annual installments over four years starting on the first anniversary of the grant date and become exercisable four years after grant, subject to performance and service conditions.
BioNTech SE Chief Operating Officer Sierk Poetting reported an indirect open-market sale of 50,000 Ordinary Shares. The shares were sold at an average price of $110.5592 per share and are held through Tofino GmbH, a company of which Poetting is the sole shareholder.
After this transaction, indirect holdings reported for Poetting through Tofino GmbH total 399,387 Ordinary Shares. This filing reflects a net sale, with no option exercises or derivative transactions disclosed in this report.